Free Trial
NASDAQ:SVRA

Savara Q4 2023 Earnings Report

Savara logo
$3.06 +0.06 (+1.83%)
Closing price 03:59 PM Eastern
Extended Trading
$2.89 -0.17 (-5.40%)
As of 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Savara EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Savara Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Savara Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Thursday, March 7, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Savara's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Savara Earnings Headlines

Savara: Make-It-Or-Break-It Molbreevi BLA Filing
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Savara Announces New Employment Inducement Grant
See More Savara Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Savara? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Savara and other key companies, straight to your email.

About Savara

Savara (NASDAQ:SVRA)., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

View Savara Profile

More Earnings Resources from MarketBeat